ReviewDiagnostic cytopathology2020
Role of TFF3 as an adjunct in the diagnosis of Barrett's esophagus using a minimally invasive esophageal sampling device-The Cytosponge
Review in Diagnostic cytopathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Unsedated transnasal endoscopy for the detection of Barrett's esophagus: systematic review and meta-analysis.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2023Pooled it
- Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.Lancet (London, England) · 2020Trial
- VSIG10L is a major determinant of esophageal homeostasis and inherited predisposition to Barrett's esophagus.Nature communications · 2026Article
- Emerging Biomarkers for Managing Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026Review
- Diagnostic Test Accuracy of Cytosponge-Trefoil Factor 3 for Barrett Esophagus: A Systemic Review and Meta Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA.Frontiers in oncology · 2025Review
- Clinical application of capsule sponge testing in symptomatic reflux disease: a national prospective cohort study.BMC gastroenterology · 2024Article
- The Aberrant Expression of Biomarkers and Risk Prediction for Neoplastic Changes in Barrett's Esophagus-Dysplasia.Cancers · 2024Article
- Enabling large-scale screening of Barrett's esophagus using weakly supervised deep learning in histopathology.Nature communications · 2024Article
- DNA methylation markers in esophageal cancer.Frontiers in genetics · 2024Review
- Real-world implementation of non-endoscopic triage testing for Barrett's oesophagus during COVID-19.QJM : monthly journal of the Association of Physicians · 2023Article
- Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Article
- Computational pathology aids derivation of microRNA biomarker signals from Cytosponge samples.EBioMedicine · 2022Article
- Triage-driven diagnosis of Barrett's esophagus for early detection of esophageal adenocarcinoma using deep learning.Nature medicine · 2021Article
- Minimally invasive esophageal sponge cytology sampling is feasible in a Tanzanian community setting.International journal of cancer · 2021Article
- Screening for Barrett's Oesophagus: Are We Ready for it?Current treatment options in gastroenterology · 2021Review
- Use of Cytosponge as a triaging tool to upper gastrointestinal endoscopy during the COVID-19 pandemic.The lancet. Gastroenterology & hepatology · 2020Article
- Novel Screening Alternatives for Barrett Esophagus.Gastroenterology & hepatology · 2020Article
- Recent advances in understanding and preventing oesophageal cancer.F1000Research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The incidence of esophageal carcinoma continues to increase whilst its prognosis remains poor. The most dramatic reduction in mortality is likely to follow early diagnosis of the preinvasive precursor lesion, Barrett's esophagus (BE), coupled with treatment of dysplastic lesions. The major risk factor for BE is gastroesophageal reflux disease, however this is highly prevalent and only a small proportion of individuals have BE, therefore an endoscopy-based screening strategy to detect BE is unfeasible. Minimally invasive esophageal sampling devices offer an alternative, cost-effective strategy which can be deployed within an at-risk population in a primary care setting to identify individuals with probable BE who can then be referred for endoscopic confirmation. The device that has currently progressed furthest in clinical trials is the Cytosponge
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.